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ABSTRACT
Introduction: Indoor air-related conditions share
similarities with other conditions that are characterised
by medically unexplained symptoms (MUS)-a
combination of non-specific symptoms that cannot be
fully explained by structural bodily pathology. In cases
of indoor air-related conditions, these symptoms are
not fully explained by either medical conditions or the
immunological–toxicological effects of environmental
factors. The condition may be disabling, including a
non-adaptive health behaviour. In this multifaceted
phenomenon, psychosocial factors influence the
experienced symptoms. Currently, there is no evidence
of clinical management of symptoms, which are
associated with the indoor environment and cannot be
resolved by removing the triggering environmental
factors. The aim of this study is to compare the effect
of treatment-as-usual (TAU) and two psychosocial
interventions on the quality of life, and the work ability
of employees with non-specific indoor air-related
symptomatology.
Methods and analyses: The aim of this ongoing
randomised controlled trial is to recruit 60 participants,
in collaboration with 5 occupational health service
units. The main inclusion criterion is the presence of
indoor air-related recurrent symptoms in ≥2 organ
systems, which have no pathophysiological
explanation. After baseline clinical investigations,
participants are randomised into interventions, which
all include TAU: cognitive-behavioural psychotherapy,
psychoeducation and TAU (control condition).
Health-related quality of life, measured using the
15D-scale, is the primary outcome. Secondary
outcomes include somatic and psychiatric symptoms,
occupational factors, and related underlying
mechanisms (ie, cognitive functioning). Questionnaires
are completed at baseline, at 3, 6 and 12-month follow-
ups. Data collection will continue until 2017. The study
will provide new information on the individual factors
related to indoor air-associated symptoms, and on ways
in which to support work ability.
Ethics and dissemination: The Coordinating Ethics
Committee of the Hospital District of Helsinki and
Uusimaa, Finland, has granted approval for the study.
The results will be published in peer-reviewed journals.
Trial registration number: NCT02069002; Pre-
results.
INTRODUCTION
Medically unexplained or functional symp-
toms (MUS) consist of a combination of
symptoms without pathophysiology.1–4 These
non-speciﬁc symptoms may occur concur-
rently with similar disease symptoms and in
various organ systems, including respiratory
systems.5 6
A combination of indoor air-associated
symptoms, including respiratory, mucosal
and skin, as well as general symptoms, are
common in non-industrial work environ-
ments.7 In some patients, symptoms persist
despite building up remediation or removal
of the factors that provoke indoor air symp-
toms;8–13 these are not explained by either
asthma or other medical conditions, and
thus remain medically unexplained.8 13
Strengths and limitations of this study
▪ Evidence-based treatments that may effectively
reduce indoor air-associated medically unex-
plained or functional symptoms, and support the
health-related quality of life are urgently needed.
▪ We use manualised treatments for the condition.
▪ The study protocol is carried out with occupa-
tional health services through multicentre
collaboration.
▪ Difficulties in the recruitment process may chal-
lenge the implementation of the study.
▪ The length of the follow-up may lead to partici-
pant drop out.
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In addition to MUS, non-speciﬁc chronic symptoms asso-
ciated with indoor air overlap with the idiopathic envir-
onment intolerance (IEI) proposed by the International
Programme on Chemical Safety (IPCS).14 IEI is deﬁned
as multiple, recurrent symptoms associated with various
environmental factors that are generally tolerated at low
levels, as well as with signiﬁcant lifestyle or functional
impairments related to these symptoms.14–16 Both func-
tional symptomatologies and IEI may lead to consider-
able disability and diminish the quality of life.17
Psychological factors such as cognitive functioning,
perceptions of health outcomes, and emotional issues
are associated with poorer physical health outcomes18
and combine with MUS and IEI. Illness perceptions and
worry, for example, have been shown to lead to higher
symptom reports in chronic diseases, such as asthma,5 19
in concordance with MUS20–22 and IEI.23 24 Challenging
these dysfunctional illness perceptions may improve
health outcomes.18 As in the treatment of chronic
medical disorders, such as asthma, individual factors
related to health behaviour25 must be taken into
account in indoor air-related symptomatology.
Moreover, in MUS, predisposing factors (ie, negative
affectivity and early life experiences) and perpetuating
factors (ie, cognitive processes including external or a
monocausal attributional styles, illness worry and rumin-
ation, illness behaviour and emotional distress) are
related to symptom maintenance.26–28 These factors
interact with prolonged physiological activation to
produce symptoms of chronic stress.29 The ﬁndings also
support the hypothesis that worry and perseverative cog-
nition are related to the enhanced activity of physio-
logical markers that act directly on somatic symptoms,
including pain, coughing and breathing difﬁculties.30
The vicious circle of cognitive, behavioural, physical and
emotional factors has been shown to predict MUS.22
Indoor air-associated symptoms are inﬂuenced by
physical, psychosocial and personal factors, often
through multiple mechanisms.31 32 Thus, the manage-
ment of symptoms associated with indoor air requires a
multifactorial approach (ﬁgure 1). In randomised con-
trolled trials of MUS, cognitive-behavioural interven-
tions, including patient education, activity regulation
strategies and illness attribution replacement from
monocausal or catastrophising to more adaptive strat-
egies, have shown to be effective for patients suffering
from MUS.27 33–36 The goal of cognitive-behavioural
psychotherapy (CBT) is to identify factors that maintain
Figure 1 Cognitive-behavioural model of hypothesised cycle of symptom perpetuation (extended after Deary et al27) and the
focus of the present RCT study (encircled). The focus is part of a multifactorial approach to managing symptoms associated with
indoor air. RCT, randomised controlled trial.
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symptomatology, and support adaptive attributional
styles and patient strengths so that quality of life is
mediated via better health behaviour and symptom
regulation. In addition, a relaxation technique called
applied relaxation (AR)37 has shown to be effective in
reducing physiological arousal related to stress through
relaxation and support of stress management.38 So far,
information regarding effective treatment options for
indoor air-associated persistent symptomatologies is
scarce.13 39
In this study, we hypothesise that non-speciﬁc symp-
toms associated with indoor air share features with MUS,
and could be treated according to similar principles. In
our previous study, tertiary care patients with symptoms
associated with indoor air that had features of MUS did
not respond to limited counselling.13 A plausible explan-
ation might have been the long symptom history, which
requires more intensive interventions. The aim of the
present clinical trial is to investigate the effectiveness of
two psychosocial treatments in comparison to
treatment-as-usual (TAU) for persistent indoor air-
associated symptoms among occupational primary
healthcare patients. The primary outcome is improved
quality of life. The secondary aim is to investigate
whether the treatments decrease patients’ overall symp-
toms and improve work ability, and to identify the
psychological factors that affect the patients’ responses
to the treatment.
METHODS
Study population
The participants of this study are recruited from occupa-
tional health service (OHS) units and their eligibility is
assessed by an occupational physician (OP) and an occu-
pational health nurse (OHN). The participants must
have recurrent multiorgan symptoms that are attributed
to workplace indoor air, including respiratory symptoms
and disability with no medical explanation. For symptom
deﬁnition we use the IEI criteria (table 1) according to
which the obvious medical diseases and exposure-related
factors that could explain the symptoms, and affect the
outcome of the intervention are excluded from OHS
before enrolment (table 1. Exclusion criteria). Patients
enrolled at the Finnish Institute of Occupational Health
(FIOH) undergo an additional clinical evaluation of
respiratory symptoms to distinguish asthma symptoms
from functional respiratory symptoms.
Study design
This study is an ongoing randomised controlled super-
iority trial (RCT) of three parallel groups. The original
Table 1 Inclusion and exclusion criteria of study
Criteria Description
Inclusion
Age and gender Age 25–58 years, female and male
Symptom
definition*
(A) Self-reported symptoms attributed to indoor work environment (non-industrial workplaces) include
(1) respiratory symptoms, and (2) symptoms in at least one of the other organ systems,
(B) Symptoms recurrently (1) occur in more than one indoor environment, or (2) continue despite
measures at the workplace to solve the indoor air problem (eg, work arrangements and/or workplace
reparations), and
(C) Symptoms are not adequately explained by medical reasons (symptoms are medically
unexplained)†
Symptom duration Onset of recurrent symptoms with disability of ≤3 years before the study
Work Employed for ≥3 years before the study
Sick leave At least 1 day of sick leave due to indoor air symptoms during the preceding 6 months
Language Fluent Finnish (writing/reading/speaking)
Exclusion
Sick leave
duration
≥6 months of sick leave due to indoor air symptoms during the preceding 2 years and currently unable
to work
Changes in work Changes in work (eg, retirement, study leave, pregnancy, etc.) during the study
Medical reasons† Some serious and/or acute untreated medical disease or illnesses:
A. Somatic disease that explains the symptoms (eg, uncontrolled asthma, and/or disease causing
disability)
B. Psychiatric disorder (depression, moderate or severe; bipolar disorder; psychotic disorders;
obsessive-compulsive disorders; eating disorders; and/or severe personality disorders)
C. Alcohol and/or drug dependency or abuse
D. Developmental disorders
Psychotherapy Psychotherapy (current or ended during two preceding years)
Other Patient refusal; not actively participating in work life (retired or unemployed)
*IEI-criteria modified from Lacour et al.15
†Based on evaluation of occupational physician. Other criteria may also be evaluated by occupational health nurse.
IEI, idiopathic environment intolerance.
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study plan included four arms: individual CBT, psychoe-
ducation, TAU and group ‘administered’ AR. The arm
(AR) requiring group formation was excluded from the
protocol due to difﬁculties in the recruitment process
(ﬁgure 2). The study is carried out by FIOH in collabor-
ation with ﬁve large OHS units, including three public
and two private enterprises in the district of Helsinki
and Uusimaa, Finland. The inclusion and exclusion cri-
teria were piloted in OHS A before enrolment. The par-
ticipant ﬂow, data collection and intervention
programme timeline is outlined in ﬁgure 2.
Before enrolling participants for the intervention, the
OPs and OHNs participate in a 1–1.5-hour training
session led by the researchers (AV, SS). Each recruiter
receives a personal recruitment manual including the
following: a description of the study procedure, inclu-
sion/exclusion criteria, patient information, informed
consent, questionnaire on indoor air factors and
arrangements at the workplace and prepaid envelopes
for returning the enrolment documents. The manual
also contains a non-identiﬁable inquiry to collect the
reasons for refusing to participate in the study despite
meeting inclusion criteria. Information letters (eg, in
OHS unit and on the intranet) are available for the use
of OHS to inform employees and employers of ongoing
study collaboration. The researchers are regularly in
contact with the recruiters during enrolment in order to
maintain the recruitment.
Before informed consent, participant candidates
receive oral and written information on the study from
Figure 2 Flow chart of study. *OHS (A to E) join the study consecutively: (A and B) in January 2014, (C) in June 2014, (D) in
August 2014, and (E) in March 2015. Participant recruitment began: (A and B) in 24th February 2014, (C) in July 2014, (D) in
September 2014 and (E) in May 2015. **AR Group Therapy discontinued during study due to slow, prolonged recruitment
process. FIOH, Finnish Institute of Occupational Health; OHS, occupational health service.
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their OHS specialists. All recruited participants preﬁll a
questionnaire and attend a medical evaluation of
respiratory symptoms at FIOH, which includes a 2-week
diurnal measurement of peak expiratory ﬂow and bron-
chial hyperresponsiveness.40 41 A respiratory physician
(HS) evaluates the results, and each participant receives
a report. In cases of uncontrolled asthma or if other
exclusion criteria are revealed, the participant is
excluded.
Before the participants are recruited, they are allo-
cated into the three arms of the study by pre-
programmed randomisation into numerical listing. The
groups are stratiﬁed to contain participants from differ-
ent OHS units, workplaces and genders with an alloca-
tion ratio of 1:1:1. After the clinical investigations,
investigators (SS and AV) allocate eligible participants
into either intervention conditions or the control (TAU)
conditions that are next in order in listing after stratiﬁca-
tion. Each group contains 20 individuals. The ﬁrst
author contacts participants by telephone and email to
inform them of their allocation after randomisation.
During the study, all participants receive TAU based on
individual needs from their OHS. Participants are asked
for permission to use their medical records for evaluat-
ing TAU during the study. They reply to web-based ques-
tionnaires through a secure internet connection at
baseline, and then at follow-up at 3, 6 and 12 months.
The conﬁdentiality of the participants is protected by
using an encryption key for personal details in the data.
The participants are recruited during the period from
February 2014 to autumn 2016 (the closing date will be
decided in early autumn 2016 after recruitment status is
updated, and this will be sometime at the end of 2016).
The aim was to recruit 80 participants in total. During
the ﬁrst 6 months, seven eligible participants were
recruited who constituted 30% of the 6-month aim.
During the next 6 months, 11 eligible participants were
recruited. After 1 year of recruitment, the low number
of participants (N=18) showed that it was difﬁcult to
ﬁnd eligible individuals. Therefore, so as not to overex-
tend the waiting period and logistics of the interven-
tions, the AR group therapy arm of the study was
discontinued, and participants were randomised into
the two individual interventions and TAU. In May 2015,
after agreement with the study steering group (April
2015), and approval from Ethics Committee’s for the
change in the study plan , the AR arm was removed
from study interventions to ensure completion of the
study. Thus, the number of recruited participants
decreased to a total of 60. The follow-up results are
expected 12 months after the last recruited participant
enters the study (approximately, in the spring of 2017),
and the preliminary results are expected during 2017.
Intervention
The intervention programmes were developed at
FIOH on the basis of previously studied intervention
protocols for multiple similar symptomatology
conditions.13 33 34 36 38 42 All interventions are described
in detail in the intervention manuals (in Finnish).
Depending on the participants’ approval, all CBT and
psychoeducation sessions are recorded for post hoc reli-
ability, and checked to ensure intervention integrity so
that the intervention is implemented as intended.43
Individual CBT
CBT consists of 10 manualised sessions. The ﬁrst 90 min
introduction is followed by nine 45 min individual ses-
sions at weekly intervals, and the last two sessions at
2-week intervals. One booster session will be conducted
3 months after treatment ends. The sessions include
information on stress-related exacerbation of indoor air-
associated symptoms and personal health behaviour
factors integrated into the patients’ own symptomatol-
ogy; cognitive restructuring behavioural training for
patients’ health-promoting behaviour at home between
the sessions; imagery rescripting; and relapse prevention
(table 2). CBT sessions are delivered by three psycholo-
gists licensed to be psychotherapists. The psychologists
Table 2 Summary of contents of CBT sessions
Sessions Contents
1 Treatment overview and description of
treatment as intervention focusing on
behavioural training and monitoring. Situation
analysis, patient’s symptoms and establishing
rapport. Setting of personal goals for the
intervention and filling of first part of
symptom-emotion-cognition-monitoring form.
2–3 Discussion on how stress affects patients’
health and physiological consequences of
stress. Coping strategies for stress and stress
decreasing activities. Working with illness
worries and symptom-perception interaction.
4–5 Personal strengths and the vicious circle of
symptom behaviour. Patient’s dysfunctional
health and indoor air related beliefs, for
example, catastrophising and cognitive
restructuring.
6–7 Evaluation of goals, discussion of obstacles
that interfere with achieving them. Validation of
frustration and support of meaningful activities.
Patient stress-reducing techniques and
work-related activities.
8–9 Health-related information and discussion on
how to react to contradictory information
regarding health-related issues. Increased
awareness of emotions and how these affect
symptom perception.
10 Identifying warning signs that may affect
recurrence of symptoms and working with
patients to plan future actions if symptoms
recur.
11 Follow-up and booster session 3 months after
intervention.
CBT, cognitive-behavioural psychotherapy.
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had clinical experience of 6–13 years, during which they
had undergone 4 years of psychotherapy training (cogni-
tive, cognitive-behavioural and integrative psychother-
apy), and had worked as psychotherapists for 0.5–7 years
before the study. To ensure treatment integrity,43 the psy-
chotherapists attended training sessions before the treat-
ment and were supervised during the treatment.
Training was arranged by the researchers (AV, SS), and
detailed intervention materials, which speciﬁed the
content of each session (eg, dosage), were provided.
Individual psychoeducation intervention
This is one manualised 90 min individual session deliv-
ered by a psychologist (SS) and a specialist in occupa-
tional medicine (AV). The intervention includes (1) an
overview of the main indoor exposures, (2) general
information on the symptoms and health risks associated
with the indoor environment, and (3) information
regarding factors that affect individual health behaviour
and symptom management (table 3).
AR group therapy
The original study plan included an arm with AR group
therapy delivered by two psychologists. This consisted of
seven manualised face-to-face sessions: one 120 min group
session followed by six 90 min sessions, as described
earlier.37 44 The sessions were planned to be delivered at
weekly intervals, the last two sessions at 2-week intervals,
and a booster session 3 months after the treatment ended.
The intervention was intended to include behavioural
training focusing on AR techniques, and a discussion of
AR as a coping strategy that can be used in cases of acute
symptoms, and for symptom and relapse prevention. As
described earlier, AR was later removed from the protocol
due to difﬁculties in the recruitment process.
Ethics, data protection and dissemination
The interventions are blind to the data collected and
the characteristics of individuals. The conﬁdentiality of
the participants is protected by an encryption key to per-
sonal data. The key is stored separately. All data are
treated and implemented according to national data
security laws. The results will be published in a peer-
reviewed journal and presented at conferences.
Outcome measures
The study is designed to evaluate the effectiveness of dif-
ferent psychosocial interventions for the health-related
quality of life, measured using the 15D scale as the
primary outcome.45 46 The 15D is a generic,
15-dimensional standardised measure composed of phys-
ical, mental and social well-being. The dimensions
include mobility, vision, hearing, breathing, sleeping,
eating, speech, elimination, usual activities, mental func-
tion, discomfort and symptoms, depression, distress,
vitality and sexual activity. Each dimension has ﬁve
grades of severity (1=the highest/best level; 5=the
lowest/worst level). In this study, the 15D is used as a
single sum score measure with values from 1 (full
health) to 0 (dead) as a primary outcome, but a proﬁle
can also be presented as descriptive data. In addition,
we also measure secondary outcomes such as work
ability and job strain, cognitive and emotional function-
ing and psychiatric symptoms (table 4). Background
information, such as medical history and work ability, is
also collected. The description and chronology of the
assessments are shown in table 4.
Sample size
Sample size was calculated in order to detect a clinically
signiﬁcant difference between the treatment arms in
primary outcome measure 15D, the single index score
ranging from 0 (dead) to 1 (full health). As a measure
of clinical signiﬁcance, we used a SD of 0.03, as based
on a nationally representative standardisation of the 15D
scale.75 According to the power analyses, an estimate of
the required sample size is N=20 eligible participants
per group. It was assumed that ∼30% (one of three)
recruited patients would not meet the inclusion criteria
when examined at FIOH. It is further assumed that the
follow-up attrition will be ≤20%. Thus, to achieve a sig-
niﬁcance level of 0.05 when requiring 80% power, a
sample size of N=17 participants per group is needed to
ﬁnd a clinically signiﬁcant difference of SD=0.03 in 15D
between the arms.
Plan of statistical methods
Before the analyses, the group allocation (TAU, psychoe-
ducation or CBT) will be concealed at FIOH by a
researcher who is not involved in the trial. Summary statis-
tics (frequencies, means and SD) of baseline and
follow-up data will be analysed and reported. The level of
signiﬁcance will be set at p<0.05. Categorical outcomes will
be analysed using the χ2 test or Fisher’s exact test. When
appropriate, we will use the t-test and the Mann-Whitney U
test to compare the baseline and follow-up outcomes of
Table 3 Outline of psychoeducation
Session Contents
90 min Information and discussion on:
▸ Factors related to indoor air-associated
symptoms: environment, risk communication
and management of the problems, reflection
on individual situation;
▸ Explanation of indoor air-associated
symptoms and diseases based on current
scientific knowledge;
▸ Physiological consequences of acute and
chronic stress;
▸ Stress management: reducing physiological
arousal through adaptive activities and
decelerating vicious circle of
emotion-behaviour-symptom-cognitions.
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the groups. Analysis of variance or covariance will be used
for multiple comparisons of the groups, and for examin-
ing changes in the groups. Item-level missing or error
values due to coding are not expected because of the com-
puterised forced protocol for the questionnaire. We will
use both analysis of study completers and an
intent-to-treat-analysis, meaning that each missing value is
replaced by the last observed value of that questionnaire to
handle drop-out data. Post hoc analysis will be used to
evaluate the individual factors related to the effectiveness
of the interventions, and additional per protocol analysis
will also be conducted. Statistical analyses will use the latest
version of IBM-SPSS for Windows (SPSS Illinois, Chicago,
Illinois, USA) software.
DISCUSSION
This study examines the efﬁcacy of psychosocial inter-
ventions among primary patients with OHS who have
symptoms associated with indoor air in multiple organ
systems and a disability with no medical explanation. In
addition, the study aims to identify the psychological
factors that affect the patients’ response to the treat-
ment. The focus is to decrease the non-speciﬁc
Table 4 Assessments and their time schedule
Assessment and evaluation method
Time of measurement (months)
<0 BL 3 6 12
Primary outcome
15D instrument*45 46 Q X X X X
Secondary outcomes
Occupational functioning
Self-assessed work ability47 Q X X X X
Job strain48 49 Q X X
Need for Recovery (NRF)50 Q X X X X
Psychiatric symptoms
Generalised Anxiety Disorder 7 (GAD-7)*51 Q X X X X
Insomnia Severity Index (ISI)*52, In Finnish53 Q X X X X
The Symptom Checklist-90 (SCL-90)*54 55 In Finnish56 Q X X X X
The Patient Health Questionnaire (PHQ-9)57; In Finnish58 Q X X X X
Cognitive and emotional functioning
The Acceptance and Action Questionnaire-II (AAQ-II)59 60
in Finnish, Tuomisto M. 2007 and 2011
Q X X X X
Illness Worry Scale (IWS)61 62 Q X X X X
Penn State Worry Questionnaire (PSWQ)63 in Finnish, Tuomisto M. 2002 Q X X X X
Strategy and Attribution Questionnaire (SAQ)*64 Q X X X
Assessment of treatment alliance and satisfaction
Working Alliance Inventory (WAI)†65 66 Q
Treatment satisfaction‡67 Q X X X
Background variables
Demographics (age, gender, marital status, education) Q X
Clinical characteristics
Health, diagnosed diseases and medication Q X X
Alcohol Use Disorders Identification Test (Audit)*68 Q X X
Asthma Control Test (ACT)§69 Q X X
General symptoms Q X X X X X
Peak Expiratory Flow (PEF)-measurements for 2 weeks41 L X
Bronchial hyper-responsiveness40 L X
The Quick Environmental Exposure and Sensitivity Inventory (QEESI)70 Q X X
Home environment Q X X
Work characteristics and occupational functioning Q X X
The Holmes and Rahe stress scale71 Q X X X
Personality and social functioning functions
Short Five (S5) personality inventory*72 Q X
The Inventory of Interpersonal Problems (IIP)73 Q X X
Sense of Coherence (SOC-13)*74 Q X X
*Psychometric properties of the Finnish population are good.
†In the Cognitive Behaviour Therapy arm, the participants and the psychotherapists fill the Working Alliance Inventory (WAI) after first, fifth
and last (10th) session.
‡In the psychoeducation arm, the participants answer the 5-question Treatment Satisfaction questionnaire.
§The Finnish version of the ACT. The ACT is a trademark of Quality Metric Incorporated 2002 GlaxoSmithKline.
BL, baseline; L, medical investigation; Q, questionnaire.
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symptoms and disability associated with the indoor envir-
onment. Our previous study among tertiary care patients
with long-lasting symptoms and disability showed that
psychosocial factors also32 have a substantial inﬂuence
on the symptoms experienced in indoor environments.13
This RCT is conducted to provide evidence of the
beneﬁt of early intervention for OHS patients. To the
best of our knowledge, there are no previous studies in
similar settings.
The strength of this study is that the participants are
recruited from OHS, which is part of Finland’s overall
primary healthcare and covers almost 90% of the
working population.76 OHS focuses on preventing work-
related diseases, and promotes health and work ability
through measures at workplaces. For a great deal of
employees, OHS also provides general healthcare and
treatment. This enables us to evaluate the usefulness of
the psychosocial interventions in the OHS context. In
this study, the participants are clinically investigated by
the recruiting OPs, and the additional clinical examin-
ation at FIOH ensures that there is no medical condition
behind the patient’s symptomatology and disability.
Detailed data of the measures taken at the workplace
and the participants’ health status are also recorded.
The longitudinal follow-up design increases the strength
of the evaluation’s effectiveness.
The possible health effects of physical, biological and
chemical factors in the indoor environment have been
extensively studied but, so far, the role of toxicological
mechanisms in the real life human exposure situations
for these problems has remained ambiguous.24 77 Along
with these indoor environmental factors, it is crucial to
understand the patients’ illnesses and recovery pro-
cesses. Compared to the standard treatment for chronic
diseases, such as asthma, the results provide evidence of
the potential beneﬁt of psychosocial management pro-
grammes that measure, for example, asthma-speciﬁc
quality of life and reduced asthma severity scores.78 79
Our focus is on individual factors related to the recovery
process and outcome.
Certain study limitations deserve attention.
Occupational and organisational changes may have an
impact on motivation to participate and stay in the
study. Possible changes in OHS systems (eg, if the
employer changes OHS provider during the study) may
also affect the recruiting process. In addition, selection
bias may exist if those who volunteer to participate are,
for example, more interested in psychosocial treatment
than the non-participating employees. Some data show
that patients’ expectations may affect treatment out-
comes.80 81 On the other hand, 10 CBT sessions, includ-
ing homework and practising, requires longer
commitment to treatment than limited psychoeducation.
This might increase the drop-out rate in the CBT group.
Moreover, during the waiting period, participants are
contacted, clinically examined and randomised; this may
have a placebo effect on a patient’s condition. This in
turn may weaken intervention effects.
In spite of the public concern regarding building
related health problems, until now, the study recruitment
has been unexpectedly slow. Challenges in recruitment
processes indicate that cultural models and the popula-
tion’s attitudes to indoor air-related symptoms need to be
evaluated. In biomedical healthcare settings, underesti-
mation of the psychosocial dimensions of the distress
associated with somatic syndromes and a patient’s fear of
stigmatisation may lead to under-treatment of the
illness.82 Moreover, patients with MUS and IEI typically
provide monocausal or deﬁnitive attribution to environ-
mental or biological factors.20 28 However, taking only
one perspective of these multifaceted phenomena in
MUS and IEI cases would diminish effective treatment
options, and thus challenge the present study which
focuses on improving stress reduction and health behav-
iour. These societal factors might bias the study popula-
tion. The participants are chosen using well-deﬁned
inclusion and exclusion criteria in order to diminish het-
erogeneity among the study participants, and to avoid
evident confounding factors that may affect the trial. In
this study, we compare psychosocial interventions to
standard treatment and we can estimate the individual
factors related to the effectiveness of the interventions in
post hoc analysis within the treatment groups. We cannot,
however, examine the effectiveness of the interventions
themselves or, for example, determine which aspects
(special contents, intervention length, etc) explain the
possible differences between the groups.
Our randomised controlled trial will provide new
information on the possible beneﬁcial effects of psycho-
social interventions on non-speciﬁc symptoms associated
with indoor air. The results will hopefully improve
evidence-based practices that intervene in indoor air-
associated symptomatologies.
TRIAL STATUS
This study has been registered at the ClinicalTrials.gov
registry (NCT02069002). Patient enrolment began on 24
February 2014, and is planned to continue until approxi-
mately the end of 2016 (based on the steering group’s
decision taken on 6 April 2016). Results from the study
are expected in 2017.
ETHICS AND DISSEMINATION
The Coordinating Ethics Committee of the Hospital
District of Helsinki and Uusimaa, Finland, has granted
approval for this study (number 107/13/03/00/13).
The study is registered and data is handled in accord-
ance with the Personal Data Act (523/1999). FIOH is
the data controller.
The results will be published in peer-reviewed jour-
nals. All results will be reported without any identiﬁable
personal information. Participation in the study will have
no effect on the participants’ healthcare. Neither OHS
nor the participant’s employer will receive any informa-
tion on study participation, or any personal study results.
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No side effects or serious risks are expected from partici-
pation in psychoeducation or cognitive behavioural psy-
chotherapy. However, if any should occur during the
treatment, the participants will be offered individual
counselling from the medical person in charge of the
study, and be referred for relevant treatment elsewhere,
if considered appropriate.
STUDY MONITORING
The research trial procedures will be audited by the steer-
ing group every 6 months. The steering group monitors
and evaluates data management and if necessary, requests
changes to the protocol. If the protocol is modiﬁed,
the approval of the ethics committee is requested, and
the ClinicalTrials.cov registry is informed. All authors will
be given access to the cleaned data sets. A separate data-
monitoring committee was not considered necessary as
the risks to participants were expected to be minimal.
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